Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy
Arteriosclerosis, Thrombosis, and Vascular Biology · 2025
DOI: 10.1161/atvbaha.124.322336 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2025. Verfasst von Esther Reijnders und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chemistry and Laboratory Medicine (E.R., L.R.R., F. P.H.T.M.R., C.M.C.), Leiden University Medical Center, the Netherlands. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized, Anticholesteremic Agents, Apolipoproteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Residual cardiovascular risk remains, despite achieving low-density lipoprotein cholesterol targets with high-intensity statins. Traditional risk scores are suboptimal. This study evaluated the prognostic utility of a 9-plex apolipoprotein panel in recent patients with acute coronary syndrome on statins and its role in predicting treatment benefit by alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, enabling precision medicine. METHODS: Baseline serum samples from 11 843 participants in the ODYSSEY OUTCOMES trial ( https://www.clinicaltrials.gov ; Unique identifier: NCT01663402) were analyzed using mass spectrometry to measure Apo(a), ApoA-I, ApoA-II, ApoA-IV, ApoB, ApoC-I, ApoC-II, ApoC-III, and ApoE. Using logistic regression, probabilities of major adverse cardiovascular events (MACE) and all-cause death over a median follow-up of 2.9 years were estimated based on baseline apolipoproteins and lipid concentrations. Clinical performance was assessed by comparing the area under the curve (AUC) of 3 models: the apolipoprotein panel, the lipid panel (total cholesterol, high-density lipoprotein cholesterol, and triglycerides), and a combination. In addition, prediction models estimating the treatment benefit of alirocumab by the apolipoprotein panel were developed. RESULTS: The prognostic performance of the apolipoprotein panel for MACE showed an AUC (95% CI) of 0.648 (0.626–0.670), compared with 0.579 (0.557–0.602) for the lipid panel. For all-cause death, the apolipoprotein panel had an AUC of 0.699 (0.664–0.733), while the lipid panel had an AUC of 0.599 (0.564–0.635). Adding the apolipoprotein panel significantly improved the performance of the conventional lipid panel ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Chemistry and Laboratory Medicine (E.R., L.R.R., F. P.H.T.M.R., C.M.C.), Leiden University Medical Center, the Netherlands.
- Department of Epidemiology and Data Science, Amsterdam UMC, The Netherlands (P.M.B.).
- Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands.
- Department of Cardiology, Netherlands Heart Institute, Utrecht (J.W.J.).
- Division of Cardiology, University of Colorado School of Medicine, Aurora (M.S., G.G.S.).
- CPC Clinical Research, Aurora, CO (M.S.).
ORCID-Profile: Esther Reijnders, Patrick M Bossuyt, J Wouter Jukema, L Renee Ruhaak, Fred P H T M Romijn, Michael Szarek, Stella Trompet, Deepak L Bhatt, Vera A Bittner, Sergio Fazio, Irena Stevanovic, Shaun G Goodman, Robert A Harrington, Harvey D White, Philippe Gabriel Steg, Gregory G Schwartz, Christa M Cobbaert
Zitieren
APA
Reijnders, E., Bossuyt, P. M., Jukema, J. W., Ruhaak, L. R., Romijn, F. P. H. T. M., Szarek, M., Trompet, S., Bhatt, D. L., Bittner, V. A., Diaz, R., Fazio, S., Stevanovic, I., Goodman, S. G., Harrington, R. A., White, H. D., Steg, P. G., Schwartz, G. G., & Cobbaert, C. M. (2025). Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.124.322336
Vancouver
Reijnders E, Bossuyt PM, Jukema JW, Ruhaak LR, Romijn FPHTM, Szarek M, et al. Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology. 2025. doi:10.1161/atvbaha.124.322336
BibTeX
@article{Reijnders2025,
author = {Reijnders, Esther and Bossuyt, Patrick M and Jukema, J Wouter and Ruhaak, L Renee and Romijn, Fred P H T M and Szarek, Michael and Trompet, Stella and Bhatt, Deepak L and Bittner, Vera A and Diaz, Rafael and Fazio, Sergio and Stevanovic, Irena and Goodman, Shaun G and Harrington, Robert A and White, Harvey D and Steg, Philippe Gabriel and Schwartz, Gregory G and Cobbaert, Christa M},
title = {Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2025},
doi = {10.1161/atvbaha.124.322336}
}
EUVIMED